Your browser is no longer supported. Please, upgrade your browser.
Settings
DVAX Dynavax Technologies Corporation daily Stock Chart
DVAX [NASD]
Dynavax Technologies Corporation
Index- P/E- EPS (ttm)-2.10 Insider Own0.70% Shs Outstand62.35M Perf Week-1.45%
Market Cap678.95M Forward P/E- EPS next Y-1.53 Insider Trans-0.91% Shs Float61.99M Perf Month-8.87%
Income-128.00M PEG- EPS next Q-0.57 Inst Own80.70% Short Float16.15% Perf Quarter-29.97%
Sales1.50M P/S452.63 EPS this Y38.10% Inst Trans0.05% Short Ratio10.43 Perf Half Y-45.82%
Book/sh2.11 P/B5.16 EPS next Y35.40% ROA-51.40% Target Price29.33 Perf Year-50.27%
Cash/sh3.46 P/C3.14 EPS next 5Y- ROE-73.00% 52W Range10.35 - 23.85 Perf YTD-41.76%
Dividend- P/FCF- EPS past 5Y15.10% ROI-48.10% 52W High-54.34% Beta0.46
Dividend %- Quick Ratio8.70 Sales past 5Y-49.30% Gross Margin- 52W Low5.22% ATR0.65
Employees192 Current Ratio8.90 Sales Q/Q1094.30% Oper. Margin- RSI (14)38.53 Volatility5.86% 5.84%
OptionableYes Debt/Eq0.76 EPS Q/Q-54.80% Profit Margin- Rel Volume0.72 Prev Close11.29
ShortableNo LT Debt/Eq0.76 EarningsNov 05 AMC Payout- Avg Volume959.50K Price10.89
Recom1.80 SMA20-6.97% SMA50-12.69% SMA200-31.13% Volume689,906 Change-3.54%
May-10-18Upgrade JP Morgan Neutral → Overweight
Mar-08-18Reiterated Cantor Fitzgerald Overweight $25 → $27
Feb-14-18Downgrade JP Morgan Overweight → Neutral
Sep-25-17Reiterated RBC Capital Mkts Outperform $26 → $28
Sep-15-17Initiated Cantor Fitzgerald Overweight $24
Jul-31-17Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $26
Jul-31-17Upgrade JP Morgan Neutral → Overweight
May-09-17Reiterated RBC Capital Mkts Sector Perform $6 → $7
Apr-28-16Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $17
Apr-27-16Downgrade JP Morgan Overweight → Neutral
Nov-30-15Initiated RBC Capital Mkts Outperform $48
Nov-25-13Upgrade MLV & Co Hold → Buy $1.50 → $5
Feb-25-13Downgrade MLV & Co Buy → Hold
Nov-16-12Reiterated MLV & Co Buy $10 → $7.50
Jan-04-12Initiated MLV & Co Buy $8
Nov-09-10Reiterated Wedbush Outperform $6 → $8
Nov-08-10Initiated Jefferies Buy $4
May-13-10Upgrade Wedbush Neutral → Outperform $2.60 → $6
Mar-20-09Initiated Wedbush Morgan Buy $1.20
Oct-22-08Downgrade Oppenheimer Outperform → Perform
Oct-15-18 06:00AM  Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer GlobeNewswire
Oct-14-18 01:21PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Oct-10-18 10:30AM  Major Biotech Announcements Moving the Market ACCESSWIRE
Oct-09-18 10:45AM  ARWR Stock Sinks After Signing a Big Collaboration Deal InvestorPlace
06:00AM  Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress GlobeNewswire
Oct-03-18 11:26AM  Why Dynavax Technologies Corporation Stock Struggled in September Motley Fool
Oct-01-18 09:52AM  Health Care Digest: An East Bay biotech coup, a Nobel effort and an A's bobblehead American City Business Journals -5.32%
Sep-29-18 06:31PM  3 Top Stocks That Aren't on Wall Street's Radar Motley Fool
Sep-27-18 04:01PM  Dynavax to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-04-18 06:30AM  Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer GlobeNewswire
Aug-28-18 06:30AM  Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101 GlobeNewswire
Aug-19-18 09:01AM  Is Dynavax Technologies Corporation a Buy? Motley Fool
Aug-18-18 01:46AM  Edited Transcript of DVAX earnings conference call or presentation 6-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-18 08:44AM  Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation Motley Fool
Aug-14-18 07:45AM  Consolidated Research: 2018 Summary Expectations for National Instruments, Dynavax Technologies, BWX Technologies, Fossil Group, GCP Applied Technologies, and Stratasys Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-06-18 06:25PM  Dynavax Technologies (DVAX) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:20PM  Dynavax Technologies: 2Q Earnings Snapshot Associated Press
04:01PM  Dynavax Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  Dynavax Technologies Corporation to Host Earnings Call ACCESSWIRE
Jul-30-18 02:45PM  Dynavax to Host Second Quarter 2018 Financial Results Conference Call GlobeNewswire
Jul-17-18 07:31AM  Jim Cramer Weighs In On Barrick Gold, Childrens Place And More Benzinga +6.14%
Jul-16-18 07:06PM  Cramer's lightning round: The best way to add gold to you... CNBC Videos
06:50PM  Cramer's lightning round: The best way to add gold to your portfolio CNBC
Jul-09-18 07:20AM  Free Technical Research on Edge Therapeutics and Three More Biotech Equities ACCESSWIRE
Jun-28-18 06:30AM  Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs GlobeNewswire
Jun-25-18 12:05PM  Dynavax Presents Analysis of Data for Participants Aged 60 to 70 with Diabetes from its Phase 3 Trial of HEPLISAV-B® GlobeNewswire
Jun-11-18 06:30AM  Dynavax to Present at the William Blair 38th Annual Growth Stock Conference GlobeNewswire
Jun-10-18 02:00PM  Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector TheStreet.com
Jun-04-18 05:06PM  What Did Dynavax Technologies Corporations (NASDAQ:DVAX) CEO Take Home Last Year? Simply Wall St.
02:15PM  Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-19-18 02:00PM  4 Names to Watch Ahead of This Year's Key Cancer-Research Conference TheStreet.com
May-17-18 12:51PM  Should Dynavax Technologies Corporations (NASDAQ:DVAX) Recent Earnings Worry You? Simply Wall St. -13.70%
May-16-18 05:15PM  Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting GlobeNewswire
08:30AM  Market Trends Toward New Normal in Dynavax Technologies, Synergy Resources, Allscripts Healthcare Solutions, Plug Power, GameStop, and Newfield Exploration Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-14-18 05:51PM  Edited Transcript of DVAX earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 12:18PM  JPMorgan Sees Entry Point In Dynavax Ahead Of June Oncology Conference Benzinga +16.82%
May-09-18 05:03AM  Dynavax Technologies: 1Q Earnings Snapshot Associated Press
May-08-18 04:05PM  Dynavax Reports First Quarter 2018 Financial Results GlobeNewswire
May-07-18 09:07AM  Dynavax Technologies Corporation (NASDAQ:DVAX) Is Expected To Breakeven Simply Wall St.
06:30AM  Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-02-18 04:15PM  Dynavax to Host First Quarter 2018 Financial Results Conference Call GlobeNewswire
Apr-25-18 07:50AM  Wired News CDC Publishes Dynavaxs HEPLISAV-B(R) ACIP Recommendations in Morbidity and Mortality Weekly Report ACCESSWIRE
Apr-23-18 06:30AM  Dynavaxs HEPLISAV-B® ACIP Recommendations Published in the CDCs Morbidity and Mortality Weekly Report GlobeNewswire
Apr-17-18 09:07AM  Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting GlobeNewswire +6.63%
Apr-16-18 05:28PM  11 Stocks Moving In Monday's After-Hours Session Benzinga
02:10PM  Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck GlobeNewswire
09:10AM  Dynavax shares rise 14% on promising cancer conference data MarketWatch
08:41AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Apr-13-18 11:38AM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-03-18 04:30PM  Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Mar-28-18 08:28AM  What Are Analysts Saying About The Future Of Dynavax Technologies Corporations (NASDAQ:DVAX)? Simply Wall St.
Mar-15-18 06:30AM  Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-08-18 06:48AM  Dynavax Technologies reports 4Q loss Associated Press
06:30AM  Dynavax Reports Fourth Quarter and Year End 2017 Financial Results GlobeNewswire
Mar-05-18 04:30PM  Dynavax to Present at the Cowen & Co. Annual Health Care Conference GlobeNewswire
Mar-03-18 07:02AM  These 3 Stocks Shot Up 100% in 2017 -- Are They Still Buys? Motley Fool
Mar-02-18 06:30AM  Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies GlobeNewswire
Mar-01-18 04:45PM  Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-21-18 03:18PM  US panel recommends new adult vaccine against hepatitis B Associated Press
10:32AM  Dynavax Clears Heplisav-B Hurdle With CDC Recommendation Benzinga
10:04AM  Dynavax stock rises after hepatitis B vaccine recommendation by CDC immunization committee MarketWatch
09:36AM  Dynavaxs HEPLISAV-B Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults GlobeNewswire
Feb-20-18 06:30AM  Dynavax Secures $175 Million in Non-Dilutive Debt Financing GlobeNewswire
Feb-19-18 10:50AM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Feb-14-18 08:00AM  Dynavax to Present at the RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-10-18 12:00PM  Watch These Biotechs and the FDA Calendar TheStreet.com
Feb-02-18 04:30PM  Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +6.08%
07:40AM  New Research: Key Drivers of Growth for First Busey, Newtek Business Services, Lakeland Financial, Costco Wholesale, Dynavax Technologies, and Overstock Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-21-18 10:00AM  3 Stocks That Could Put NVIDIA's Returns to Shame Motley Fool
Jan-12-18 04:01PM  Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-08-18 10:18AM  Dynavax Technologies Corporation (DVAX) Announces the Launch of HEPLISAV-B in the US SmarterAnalyst
09:22AM  Want To Invest In Dynavax Technologies Corporation (NASDAQ:DVAX)? Heres How It Performed Lately Simply Wall St.
08:00AM  1 Reason Dynavax Technologies Corporation Stock Soared in 2017 Motley Fool
06:00AM  Dynavax Announces HEPLISAV-B is Now Available in the United States for the Prevention of Hepatitis B in Adults GlobeNewswire
Jan-04-18 06:00AM  Dynavax to Present at J.P. Morgan 36th Annual Healthcare Conference GlobeNewswire
Dec-29-17 12:55PM  Dynavax Technologies Corp. Value Analysis (NASDAQ:DVAX) : December 29, 2017 Capital Cube
Dec-28-17 07:19AM  Dynavax Technologies Corp. breached its 50 day moving average in a Bearish Manner : DVAX-US : December 28, 2017 Capital Cube
Dec-18-17 10:00AM  3 Growth Stocks to Own in 2018 Motley Fool
Dec-05-17 04:01PM  Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Marketwired
Nov-28-17 07:50AM  Report: Exploring Fundamental Drivers Behind Starbucks, Home Depot, Kroger, Dynavax Technologies, Kratos Defense & Security Solutions, and Medtronic New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +6.83%
Nov-27-17 04:01PM  Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference Marketwired
Nov-13-17 08:10AM  Todays Research Reports on Stocks to Watch: Dynavax Technologies and Puma Biotechnology ACCESSWIRE -9.38%
Nov-12-17 06:49PM  Cowen Anticipates Dynavaxs Now-Approved Heplisav Will Lead the HBV Vaccine Market SmarterAnalyst
12:51PM  Third times the charm: Dynavax shares rocket 18% on hepatitis B vaccine approval MarketWatch
Nov-11-17 07:23AM  It's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval Motley Fool
Nov-10-17 08:44AM  At Long Last, Dynavax Wins FDA Approval For Heplisav Benzinga
07:19AM  Dynavax stock surges 18% on hepatitis B vaccine approval MarketWatch
Nov-09-17 05:44PM  Third time's the charm: East Bay drug maker wins FDA approval for hepatitis B vaccine American City Business Journals
05:12PM  Dynavax Technologies Corporations (DVAX) Hepatitis B Vaccine Wins FDA Approval SmarterAnalyst
04:45PM  Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults Marketwired
08:37AM  Options Traders Expect Huge Moves in Dynavax (DVAX) Stock Zacks
Nov-08-17 05:58PM  ETFs with exposure to Dynavax Technologies Corp. : November 8, 2017 Capital Cube -5.01%
03:04PM  Dynavax Awaits FDA Verdict On Hepatitis B Vaccine Benzinga
01:44PM  Dynavax Technologies Corp. breached its 50 day moving average in a Bullish Manner : DVAX-US : November 8, 2017 Capital Cube
Nov-07-17 08:12AM  Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube -5.39%
Nov-06-17 10:48AM  The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket Benzinga +7.41%
08:09AM  The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical Zacks
Nov-03-17 06:34AM  Dynavax Technologies reports 3Q loss Associated Press
06:30AM  Dynavax Reports Third Quarter 2017 Financial Results Marketwired
Nov-02-17 08:54AM  5 Biotech and Pharma Stocks with Key FDA Catalysts this November Zacks
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OSTRACH MICHAEL SSenior Vice PresidentJun 08Sale15.534,00062,10076,554Jun 08 07:37 PM
Novack David FSenior Vice PresidentMar 15Sale16.3016,109262,6040Mar 16 04:40 PM
Novack David FSenior Vice PresidentMar 13Sale16.5234,214565,10516,109Mar 15 07:45 PM
Novack David FSenior Vice PresidentMar 09Sale17.972,12138,11175,521Mar 13 06:56 PM
Johnson David LouisVice PresidentFeb 05Option Exercise0.004,68809,406Feb 05 07:29 PM
Johnson David LouisVice PresidentJan 04Sale18.603,09257,5114,718Jan 05 04:35 PM
Johnson David LouisVice PresidentDec 31Option Exercise0.005,00009,688Jan 03 08:02 PM
COFFMAN ROBERTSenior Vice PresidentDec 13Option Exercise5.407,50040,50013,808Dec 15 04:47 PM
COFFMAN ROBERTSenior Vice PresidentDec 13Sale18.907,500141,7506,308Dec 15 04:47 PM